Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Ensysce Biosciences, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 21 | 21 | 0 |
| Shares | 5.47M | 3.92M | −1.54M (−28.2%) |
| Value | $6.23M | $3.41M | −$2.82M (−45.3%) |
New holders (4)
Institutions that held Ensysce Biosciences, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citigroup Inc | 70,940 | $62.0K | 0.00% |
| Two Sigma Securities, LLC | 24,034 | $21.0K | 0.00% |
| Susquehanna International Group, LLP | 15,393 | $13.0K | 0.00% |
| StoneX Group Inc. | 11,870 | $10.3K | 0.00% |
Sold out (4)
Institutions that held Ensysce Biosciences, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Virtu Financial LLC | 24,630 | $28.0K |
| Evergreen Capital Management LLC | 11,534 | $13.0K |
| Cresset Asset Management, LLC | 11,223 | $13.0K |
| FinTrust Capital Advisors, LLC | 350 | $0 |